Thaumachron was founded in 2020 by Andrew Simpson. Andrew has an extensive educational background with a BS in biochemistry (Indiana Wesleyan University), MS in bioinformatics (Johns Hopkins), MS in computer science (Johns Hopkins), a Graduate Certificate in Mining Massive Data Sets (Stanford), and a Graduate Certificate in Artificial Intelligence (Stanford). At the start of the pandemic monoclonal antibody treatments were discussed in the news, and companies were saying that monoclonal antibody treatments would be ready in just under a year and that it would be the fastest time ever. Thaumachron's founder thought that this was an extremely slow process, and he set to work to use AI to create antibodies given only an antigen's sequence. This patent pending technology is not only useful for rapid early treatments of novel viruses it's at the heart of a universal cure for cancer, autoimmune diseases and allergies.
Example: a COVID-19 protein. Using only amino acid sequences Thaumachron's AI is able to correctly fold one of COVID-19's proteins
Example: Using the previously folded protein, an antibody can be generated to target the antigen.
Example: Using BASTP, the generated antibody is found to be closely resembling the desired chain type and species.